VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Large Growth in Short Interest
by Jessica Moore · The Cerbat GemVivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 91,217 shares, a growth of 512.8% from the March 15th total of 14,885 shares. Approximately 3.6% of the shares of the stock are sold short. Based on an average daily volume of 134,350 shares, the short-interest ratio is presently 0.7 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Get Our Latest Stock Report on VIVS
Institutional Inflows and Outflows
An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent filing with the Securities & Exchange Commission. 8.23% of the stock is owned by hedge funds and other institutional investors.
VivoSim Labs Stock Down 5.2%
Shares of VivoSim Labs stock traded down $0.08 during trading on Friday, hitting $1.45. The stock had a trading volume of 22,532 shares, compared to its average volume of 114,494. The stock has a 50 day simple moving average of $1.88 and a 200 day simple moving average of $2.17. The company has a market capitalization of $3.78 million, a PE ratio of -0.46 and a beta of 1.43. VivoSim Labs has a 1 year low of $1.25 and a 1 year high of $5.30.
VivoSim Labs (NASDAQ:VIVS – Get Free Report) last released its earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.
VivoSim Labs Company Profile
VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.